Abstract
toxic drugs (multidrug resistance, MDR) is a major limitation to the successful chemotherapeutic treatment of cancer. The genetic and biochemical alterations responsible for the multidrug resistance phenotype of cancer cells have been the subject of intense investigation for more than 25 years and dramatic progress has been made in the understanding of multidrug resistance-associated genes, proteins and their mechanisms of action. Because of the inherent difficulty of studying drug resistance in Z&J (e.g. due to heterogeneity of human cancer, or difficulty in obtaining several clinical specimens from the same tumour during the course of chemotherapeutic
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call